The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1621
ISSUE 1621
April 5, 2021
Ripretinib (Qinlock) for GIST (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
April 5, 2021 (Issue: 1621)
The FDA has approved the oral tyrosine kinase inhibitor
ripretinib (Qinlock – Deciphera) for treatment of adults
with advanced gastrointestinal stromal tumors (GISTs)
who have previously received treatment with ≥3 kinase
inhibitors, including imatinib (Gleevec, and generics).
... more
- V Indio et al. Integrated molecular characterization of gastrointestinal stromal tumors (GIST) harboring the rare D842V mutation in PDGFRA gene. Int J Mol Sci 2018; 19:732.
- K Akahoshi et al. Current clinical management of gastrointestinal stromal tumor. World J Gastroenterol 2018; 24:2806.
- S Farag et al. Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates. Curr Treat Options Oncol 2020; 21:55.
- Regorafenib (Stivarga) for metastatic colorectal cancer and GIST. Med Lett Drugs Ther 2013; 55:36.
- Avapritinib (Ayvakit) for GIST. Med Lett Drugs Ther 2021; 63:23.
- BD Smith et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell 2019; 35:738.
- JY Blay et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21:923.
- J Nemunaitis et al. Intrigue: phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. Future Oncol 2020; 16:4251.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2020 September 10 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Ripretinib (Qinlock) for GIST (online only)
Article code: 1621f
Electronic, downloadable article - $45
Article code: 1621f
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian